Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-3. (Canceled).

4. (Currently Amended) A pharmaceutical composition ~~The pharmaceutical composition of claim 3, further~~ comprising

(i) an effective amount of a compound of the formula:



where

each X independently is O, S, or NR_2;

R_2 is selected from the group consisting of cyano, nitro, hydrogen, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

D is a direct bond or C_1-C_8 alkyl or alkenyl;

R is an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein when R is an alicyclic monocyclic heterocyclic ring containing a nitrogen heteroatom, the alicyclic monocyclic heterocyclic ring contains only one nitrogen heteroatom;

wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, C_1-C_4 alkoxy, C_2-C_4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;

or a pharmaceutically acceptable salt, ester, or solvate thereof;

(ii) an additional neurotrophic factor; and

(iii) a pharmaceutically acceptable carrier.

5. (Previously Presented) The pharmaceutical composition of claim 4, wherein the additional neurotrophic factor is selected from the group consisting of neurotrophic growth factor, brain derived growth factor, glial derived growth factor, cilial neurotrophic factor, insulin growth factor, acidic fibroblast growth factor, basic fibroblast growth factor, platelet-derived growth factors, neurotropin-3, and neurotropin-4/5.

6.-65. (Canceled).

66. (Currently Amended) A pharmaceutical composition ~~The pharmaceutical composition of claim 65, further~~ comprising

(i) an effective amount of a compound of the formula:



where

each X independently is O, S, or NR_2;

R_2 is selected from the group consisting of cyano, nitro, hydrogen, C_1-C_4 alkyl, hydroxy, and C_1-C_4 alkoxy;

D is a direct bond or C_1-C_8 alkyl or alkenyl;

R is hydrogen, or an alicyclic or aromatic, mono-, bi- or tricyclic, carbo- or heterocyclic ring, wherein when R is an alicyclic monocyclic heterocyclic ring containing a nitrogen heteroatom, the alicyclic monocyclic heterocyclic ring contains only one nitrogen heteroatom;

wherein R is optionally substituted with one substituent selected from the group consisting of hydrogen, halo, hydroxyl, nitro, trifluoromethyl, C_1-C_6 straight or branched chain alkyl, C_2-C_6 straight or branched chain alkenyl, C_1-C_4 alkoxy, C_2-C_4 alkenyloxy, phenyl, phenoxy, benzyloxy, and amino;

wherein when both X substituents are O and D is a bond, R is not phenyl;

wherein when one X is O and the other is S and D is a bond, then R is not phenyl;

wherein when both X substituents are O and R is H, D is not C_1-C_8 alkyl;

or a pharmaceutically acceptable salt, ester, or solvate thereof;

(ii) an additional neurotrophic factor other than said compound; and

(iii) a pharmaceutically acceptable carrier.

67.-68. (Canceled).